DIPYRIDAMOLE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C24H40N8O4
Molecular Weight	504.6265
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C1CCN(CC1)c2c3c(c(nc(n3)N(CCO)CCO)N4CCCCC4)nc(n2)N(CCO)CCO

InChI

InChIKey=IZEKFCXSFNUWAM-UHFFFAOYSA-N

InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2

HIDE SMILES / InChI

Description
Sources: http://www.drugbank.ca/drugs/DB00975
Curator's Comment:: Description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/012836s057lbl.pdf

Dipyridamole, a non-nitrate coronary vasodilator that also inhibits platelet aggregation, is combined with other anticoagulant drugs, such as warfarin, to prevent thrombosis in patients with valvular or vascular disorders. Dipyridamole is also used in myocardial perfusion imaging, as an antiplatelet agent, and in combination with aspirin for stroke prophylaxis. Dipyridamole likely inhibits both adenosine deaminase and phosphodiesterase, preventing the degradation of cAMP, an inhibitor of platelet function. This elevation in cAMP blocks the release of arachidonic acid from membrane phospholipids and reduces thromboxane A2 activity. Dipyridamole also directly stimulates the release of prostacyclin, which induces adenylate cyclase activity, thereby raising the intraplatelet concentration of cAMP and further inhibiting platelet aggregation. Used for as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement and also used in prevention of angina.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Potency
Equilibrative nucleoside transporter 1 7 Target ID: CHEMBL1997 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17636949	Inhibitor 7701	144.8 nM [IC50]
Phosphodiesterase 10A 12 Target ID: CHEMBL4409 Sources: http://www.drugbank.ca/drugs/DB00975	Inhibitor 7701	1.2 µM [IC50]
Phosphodiesterase 5A 30 Target ID: CHEMBL1827 Sources: https://www.ncbi.nlm.nih.gov/pubmed/8254606	Inhibitor 7701	0.52 µM [IC50]
Phosphodiesterase 4 49 Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9873613	Inhibitor 7701	0.5 µM [IC50]
Adenosine deaminase 11 Target ID: CHEMBL1910 Sources: http://www.drugbank.ca/drugs/DB00975	Inhibitor 7701	45.0 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Postoperative thromboembolic complications of cardiac valve replacement 1 Sources: http://www.accessdata.fda.gov/drugsatfda_docs/label/2005/012836s057lbl.pdf	Preventing		Approved 7997	Persantine Approved Use Persantine (dipyridamole USP) tablets are indicated as an adjunct to coumarin anticoagulants in the prevention of postoperative thromboembolic complications of cardiac valve replacement. Launch Date -2.54793597E11

C_max

Value	Dose	Analyte	Population
1881 ng/mL EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2173_001_PAR.pdf	200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
475 ng/mL EXPERIMENT http://ijpr.sbmu.ac.ir/article_58_c020ec0b8fe53db0e9efad50d3ee292f.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2781 ng/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2825745	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
15030 ng × h/mL EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2173_001_PAR.pdf	200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2492 ng × h/mL EXPERIMENT http://ijpr.sbmu.ac.ir/article_58_c020ec0b8fe53db0e9efad50d3ee292f.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
15779 ng × h/mL EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2825745	200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered:	DIPYRIDAMOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
10.74 h EXPERIMENT http://mri.cts-mrp.eu/download/DK_H_2173_001_PAR.pdf	200 mg 2 times / 2 weeks multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered:		DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.3 h EXPERIMENT http://ijpr.sbmu.ac.ir/article_58_c020ec0b8fe53db0e9efad50d3ee292f.pdf	25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered:		DIPYRIDAMOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

F_unbound

Value	Dose	Co-administered	Analyte	Population
1% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2001/20884s1lbl.pdf			DIPYRIDAMOLE plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
1750 mg single, oral Overdose Dose: 1750 mg Route: oral Route: single Dose: 1750 mg Sources: https://pubmed.ncbi.nlm.nih.gov/7960280 Page: p.75	healthy, 23 n = 1 Health Status: healthy Age Group: 23 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/7960280 Page: p.75	Disc. AE: Loss of consciousness, Respiratory distress... AEs leading to discontinuation/dose reduction: Loss of consciousness Respiratory distress Apnea Coma Sources: https://pubmed.ncbi.nlm.nih.gov/7960280 Page: p.75
8 g single, oral Overdose Dose: 8 g Route: oral Route: single Dose: 8 g Co-administed with:: paracetamol, p.o(8 g, single) Sources: https://pubmed.ncbi.nlm.nih.gov/23960064 Page: e15	healthy, 58 n = 1 Health Status: healthy Age Group: 58 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/23960064 Page: e15	Disc. AE: Tachycardia, Hypotension... AEs leading to discontinuation/dose reduction: Tachycardia Hypotension Multi-organ failure Delirium Anuria Renal failure Sources: https://pubmed.ncbi.nlm.nih.gov/23960064 Page: e15
200 mg 2 times / day multiple, oral Recommended Dose: 200 mg, 2 times / day Route: oral Route: multiple Dose: 200 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/11549300 Page: p.1786	unhealthy, 61 n = 198 Health Status: unhealthy Condition: Angina pectoris Age Group: 61 Sex: M+F Population Size: 198 Sources: https://pubmed.ncbi.nlm.nih.gov/11549300 Page: p.1786	Disc. AE: Headache, Diarrhoea... AEs leading to discontinuation/dose reduction: Headache (9.1%) Diarrhoea (3.5%) Nausea (1.5%) Vomiting (2%) Dyspepsia (1.5%) Sources: https://pubmed.ncbi.nlm.nih.gov/11549300 Page: p.1786
5 g single, oral Overdose Dose: 5 g Route: oral Route: single Dose: 5 g Sources: https://pubmed.ncbi.nlm.nih.gov/1567532 Page: p.62	unhealthy, 62 n = 1 Health Status: unhealthy Condition: Angina pectoris Age Group: 62 Sex: F Population Size: 1 Sources: https://pubmed.ncbi.nlm.nih.gov/1567532 Page: p.62	Disc. AE: Myocardial infarction... AEs leading to discontinuation/dose reduction: Myocardial infarction Sources: https://pubmed.ncbi.nlm.nih.gov/1567532 Page: p.62

AEs

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 1172	inhibitor 1318	inhibitor 1421	inhibitor 1360

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MRP4 194 MRP5 21 P-gp 1089 OATP1B1 698 OATP1B3 613 OATP2B1 107 BSEP 363 MRP2 341 MRP3 148 BCRP 574 MATE1 290 MATE2 258 OCT2 582 OCT1 473 CYP1A2 1268 CYP2A6 594 CYP2C19 1215 CYP2E1 761 ALDH1 33	P-gp 1223 UGT 160

Drug as perpetrator

Target	Modality	Activity
ALDH1 33	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNTc3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	inconclusive [Activation 27.71665 uM]
CYP1A2 1406	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2A6 625	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	no [IC50 >10 uM]
CYP2E1 841	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	no [IC50 >10 uM]
MRP2 421	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
MRP3 200	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/	no [IC50 >133 uM]
CYP2C19 1277	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [Activation 1.2589 uM]
CYP2D6 1455	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTMyIn19	yes [Activation 10 uM]
CYP3A4 1462	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTMyIn19	yes [Activation 10 uM]
CYP2C9 1362	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [Activation 5.0119 uM]
OCT2 583	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [IC50 2.6 uM]
MATE1 291	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [IC50 26 uM]
MRP5 45	inhibitor 2614 Sources: https://go.drugbank.com/drugs/DB00975, https://go.drugbank.com/articles/A16089, https://transportal.compbio.ucsf.edu/compounds/dipyridamole/	yes [IC50 30 uM]
BSEP 364	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/23956101/, https://go.drugbank.com/drugs/DB00975	yes [IC50 4 uM]
BCRP 639	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/16247709/	yes [IC50 4.8 uM]
P-gp 1255	inhibitor 2614 Sources: https://go.drugbank.com/drugs/DB00975, https://go.drugbank.com/articles/A15813, https://transportal.compbio.ucsf.edu/compounds/dipyridamole/	yes [IC50 40 uM]
MATE2 258	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTI3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [IC50 74 uM]
MRP4 226	inhibitor 2614 Sources: https://go.drugbank.com/drugs/DB00975, https://pubmed.ncbi.nlm.nih.gov/11856762/, https://go.drugbank.com/drugs/DB00975	yes [IC50 8.3 uM]
OCT1 488	inhibitor 2614 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDkzMiJ9fQ%3D%3D	yes [IC50 81 uM]
OATP1B1 713	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://go.drugbank.com/drugs/DB00975	yes
OATP1B3 622	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://go.drugbank.com/drugs/DB00975	yes
OATP2B1 107	inhibitor 2614 Sources: https://pubmed.ncbi.nlm.nih.gov/22541068/, https://go.drugbank.com/drugs/DB00975	yes

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
P-gp 1223	substrate 2752 Sources: https://go.drugbank.com/drugs/DB00975, https://go.drugbank.com/articles/A15849	yes
UGT 160	substrate 2752 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/020884s039lbledt.pdf Page: 7.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 1392	inhibitor 1374 Sources: https://pubmed.ncbi.nlm.nih.gov/17146843/\| https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMOTMyIn19

Sourcing

Vendor/Aggregator	ID	URL
ChEBI	CHEBI:4653	https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4653
ChemicalBook	CB6731869	https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6731869
MolPort	MolPort-001-792-504	https://www.molport.com/shop/molecule-link/MolPort-001-792-504
Selleck Chemicals	Dipyridamole(Permole,-Persantine)	http://www.selleckchem.com/products/Dipyridamole(Permole,-Persantine).html
ZINC	ZINC000000643046	http://zinc15.docking.org/substances/ZINC000000643046
eMolecules	27519521	https://www.emolecules.com/cgi-bin/more?vid=27519521
eMolecules	494752	https://www.emolecules.com/cgi-bin/more?vid=494752

PubMed

Title	Date	PubMed
A1 adenosine receptor activation increases adipocyte leptin secretion.	2000 Apr	10746648
Cloning and characterization of PDE7B, a cAMP-specific phosphodiesterase.	2000 Jan 4	10618442
Echo-dipyridamole stress test evaluation of isosorbide-5-mononitrate efficacy and tolerance in patients with coronary heart disease: interplay with sympathetic activity.	2000 Jul	10892660
Cloning and characterization of the human and mouse PDE7B, a novel cAMP-specific cyclic nucleotide phosphodiesterase.	2000 May 27	10872825
Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation.	2001	11174004
Metabolic fate of extracellular NAD in human skin fibroblasts.	2001	11135366
Antithrombotic drugs for secondary stroke prophylaxis.	2001 Apr	11310519
Repeated thromboembolic and bleeding events after mechanical aortic valve replacement.	2001 Apr	11308155
Heterogeneity of resting and hyperemic myocardial blood flow in healthy humans.	2001 Apr	11282088
Safety, feasibility, and prognostic implications of pharmacologic stress echocardiography in 1482 patients evaluated in an ambulatory setting.	2001 Apr	11275930
Prognostic value of pharmacologic stress echocardiography in patients with left bundle branch block.	2001 Apr 1	11286950
Adenosine permeation of a dynamic in vitro blood-brain barrier inhibited by dipyridamole.	2001 Apr 13	11292455
Characterization of TbPDE2A, a novel cyclic nucleotide-specific phosphodiesterase from the protozoan parasite Trypanosoma brucei.	2001 Apr 13	11134002
Antiplatelet agents in tissue factor-induced blood coagulation.	2001 Apr 15	11290593
Assessment of the effect of revascularization early after CABG using ECG-gated perfusion single-photon emission tomography.	2001 Feb	11303895
Preoperative dipyridamole-thallium scanning, selective coronary revascularization and long-term survival in patients with critical lower limb ischemia.	2001 Feb	11292913
The use of L-arginine [correction of F-arginine] and phosphodiesterase inhibitor (dipyridamole) to wean from inhaled nitric oxide.	2001 Feb	11284188
Newer antiplatelet therapies in stroke prevention.	2001 Feb	11280112
Antiplatelet therapy in the elderly. Aspirin, ticlopidine-clopidogrel, and GPIIb/GPIIIa antagonists.	2001 Feb	11270132
Antithrombotic therapy in valvular heart disease.	2001 Feb	11270129
Quantification of myocardial perfusion in human subjects using 82Rb and wavelet-based noise reduction.	2001 Feb	11216517
Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia.	2001 Feb	11213889
Effects of coronary revascularisation on myocardial blood flow and coronary vasodilator reserve in hibernating myocardium.	2001 Feb	11156674
Performance of a polyurethane vascular prosthesis carrying a dipyridamole (Persantin) coating on its lumenal surface.	2001 Feb	11093182
Aggrenox and stress testing.	2001 Feb 27	11222491
Effect of dipyridamole on ischemia and reperfusion injury of canine liver.	2001 Feb-Mar	11267134
Role of relative myocardial perfusion reserve for evaluating stenosis severity in patients with single-vessel coronary artery disease using.	2001 Jan	11153817
Congenital heart disease: current indications for antithrombotic therapy in pediatric patients.	2001 Jan	11139805
The transport of a reversible proton pump antagonist, 5, 6-dimethyl-2-(4-Fluorophenylamino)-4-(1-methyl-1,2,3, 4-tetrahydroisoquinoline-2-yl) pyrimidine hydrochloride (YH1885), across caco-2 cell monolayers.	2001 Jan	11124230
Cloning of a novel isoform of the mouse NBMPR-sensitive equilibrative nucleoside transporter (ENT1) lacking a putative phosphorylation site.	2001 Jan 10	11179696
Saphenous vein endothelial cell viability: a comparative study of endoscopic and open saphenectomy for coronary artery bypass grafting.	2001 Jan-Mar	11303993
Action of dipyridamole and warfarin on growth of human endothelial cells cultured in serum-free media.	2001 Mar	11311224
[Reporting echocardiography exams with the G8-Cardio ANMCO software].	2001 Mar	11307784
Progressive intracranial vascular disease with strokes and seizures in a boy with progeria.	2001 Mar	11305689
Dipyridamole-atropine stress echocardiography versus exercise SPECT scintigraphy for detection of coronary artery disease in hypertensives with positive exercise test.	2001 Mar	11288820
Use of dobutamine stress echocardiography in determination of myocardial viability.	2001 Mar	11280019
Myocardial flow reserve parametric map, assessed by first-pass MRI compartmental analysis at the chronic stage of infarction.	2001 Mar	11241806
Operator independent left ventricular function monitoring during pharmacological stress echo with the new peak transcutaneous acceleration signal.	2001 Mar	11179267
Direct effects of selective type 5 phosphodiesterase inhibitors alone or with other vasodilators on the erectile response in cats.	2001 Mar	11176530
Activation of glutamate uptake by guanosine in primary astrocyte cultures.	2001 Mar 26	11277601
Preliminary clinical results of photon energy recovery in simultaneous rest Tl-201/stress Tc-99m sestamibi myocardial SPECT.	2001 Mar-Apr	11295691
Prognostic value of dipyridamole SPECT imaging in low-risk patients after myocardial infarction.	2001 Mar-Apr	11295690
Dipyridamole myocardial SPECT with low heart rate response indicates cardiac autonomic dysfunction in patients with diabetes.	2001 Mar-Apr	11295689
Effect of power Doppler and digital subtraction techniques on the comparison of myocardial contrast echocardiography with SPECT.	2001 May	11303008

Patents

Sample Use Guides

In Vivo Use Guide

Adjunctive Use in Prophylaxis of Thromboembolism after Cardiac Valve Replacement. The recommended dose is 75-100 mg four times daily as an adjunct to the usual warfarin therapy.

Route of Administration: Oral

In Vitro Use Guide

Mengovirus plaque formation in HeLa or L cells was inhibited nearly 100% by the presence of 80 uM dipyridamole.

Name

Type

Language

DIPYRIDAMOLE

Official Name

English

DIPYRIDAMOLE [ORANGE BOOK]

Common Name

English

B01AC07

Code

English

DIPYRIDAMOLE [MART.]

Common Name

English

AGGRENOX COMPONENT DIPYRIDAMOLE

Common Name

English

DIPYRIDAMOLE [VANDF]

Common Name

English

DIPYRIDAMOLE [EP MONOGRAPH]

Common Name

English

DIPYRIDAMOLE [INN]

Common Name

English

RA-8

Code

English

DIPYRIDAMOLE [USAN]

Common Name

English

PERSANTINE

Brand Name

English

DIPYRIDAMOLE [WHO-DD]

Common Name

English

DIPYRIDAMOLE COMPONENT OF AGGRENOX

Common Name

English

DIPYRIDAMOLE [USP MONOGRAPH]

Common Name

English

DIPYRIDAMOLE [MI]

Common Name

English

DIPYRIDAMOLE [USP-RS]

Common Name

English

DIPYRIDAMOLE [JAN]

Common Name

English

NSC-515776

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C744